|
受注：045-509-1970 |
技術サポート：tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Ipilimumab (anti-CTLA-4)
製品コード：A2001 Batch: A200104
Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
製品説明
| CAS No. | 477202-00-9 |
|---|---|
| Formulation | PBS buffer, pH 7.2 |
| Isotype | Human IgG1 |
| Source | CHO cells |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
| Shipping | Shipped under low temperature conditions |
| Purity | 99% |
| Protein concentration | 5.33 mg/ml |
| Endotoxin Level | <1 EU/mg |
カスタマーフィードバック
.gif)
Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：
| Role of the androgen receptor in melanoma aggressiveness [ Cell Death Dis, 2025, 16(1):34] | PubMed: 39837817 |
| Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma [ Br J Cancer, 2025, 10.1038/s41416-025-03185-0] | PubMed: 41044172 |
| Sprinkling in extra validation for high-value PTMs and therapeutic Abs with MILKSHAKE Western blots and Sundae ELISAs [ N Biotechnol, 2025, 89:11-19] | PubMed: 40482963 |
| Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy [ Sci Rep, 2025, 15(1):35889] | PubMed: 41087622 |
| Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy [ Cancer Cell, 2024, S1535-6108(24)00080-1] | PubMed: 38518774 |
| A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145] | PubMed: 37190054 |
| A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145] | PubMed: 37190054 |
| Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer [ Cancers (Basel), 2023, 16(1)80] | PubMed: 38201508 |
| Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma [ Front Immunol, 2022, 13:925633] | PubMed: 36091050 |
| A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer [ Cancers (Basel), 2022, 14(12)2895] | PubMed: 35740561 |
人間や獣医の診断であるか治療的な使用のためにでない。